Pharmaceuticals: Positive phase III results for Lilly's SGLT-2 inhibitor, Jardiance. Implications for our stock universe

News published on August Friday 21, 2015
Share on

Eli Lilly and Boehringer announced that their SGLT-2 inhibitor, Jardiance (in combination with a DPP-4 inhibitor), reduced the CV risks in patients suffering from Type 2 Diabetes. We think this is good news for the whole therapeutic class. If we should retain a winner then this would be AstraZeneca given its leading position outside the US. On the other hand, companies that only have GLP-1 analogues or DPP-4 in their portfolio, like Novo Nordisk, Novartis, and, to a lesser extent, Sanofi, may suffer from this evolving paradigm.

For more indormation please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities